The estimated Net Worth of Sean Tucker is at least $753 Mille dollars as of 22 April 2022. Dr Tucker owns over 40,000 units of Vaxart Inc stock worth over $119,973 and over the last 7 years he sold VXRT stock worth over $102,000. In addition, he makes $530,720 as Sr. VP & Chief Scientific Officer at Vaxart Inc.
Dr has made over 6 trades of the Vaxart Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 40,000 units of VXRT stock worth $30,800 on 22 April 2022.
The largest trade he's ever made was exercising 40,000 units of Vaxart Inc stock on 22 April 2022 worth over $30,800. On average, Dr trades about 5,621 units every 100 days since 2018. As of 22 April 2022 he still owns at least 127,631 units of Vaxart Inc stock.
You can see the complete history of Dr Tucker stock trades at the bottom of the page.
Dr. Sean N. Tucker is the Sr. VP & Chief Scientific Officer at Vaxart Inc.
As the Sr. VP & Chief Scientific Officer of Vaxart Inc, the total compensation of Dr Tucker at Vaxart Inc is $530,720. There are 2 executives at Vaxart Inc getting paid more, with Wouter Latour having the highest compensation of $747,711.
Dr Tucker is 53, he's been the Sr. VP & Chief Scientific Officer of Vaxart Inc since . There are 9 older and 3 younger executives at Vaxart Inc. The oldest executive at Vaxart Inc is Anne VanLent, 72, who is the Independent Director.
Sean's mailing address filed with the SEC is C/O VAXART, INC., 170 HARBOR WAY, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 7 years, insiders at Vaxart Inc have traded over $322,706,538 worth of Vaxart Inc stock and bought 8,979,091 units worth $2,899,807 . The most active insiders traders include Capital, Llc Armistice Capi..., Steven Lo e Wouter Latour. On average, Vaxart Inc executives and independent directors trade stock every 57 days with the average trade being worth of $1,309,363. The most recent stock trade was executed by W. Mark Watson on 18 June 2024, trading 20,000 units of VXRT stock currently worth $13,600.
since its founding in 2004, vaxart has pursued a vision of advancing vaccines—to make them as tablets rather than injections. the company’s proprietary oral vaccine delivery platform is suitable to deliver any recombinant vaccine, positioning vaxart to introduce oral forms of multiple vaccines in the rapidly growing global vaccines market.
Vaxart Inc executives and other stock owners filed with the SEC include: